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ABSTRACT
Objectives To investigate the effects of personal calcium
supplement use on cardiovascular risk in the Women’s
Health Initiative Calcium/Vitamin D Supplementation
Study (WHI CaD Study), using the WHI dataset, and to
update the recent meta-analysis of calcium supplements
and cardiovascular risk.
Design Reanalysis of WHI CaD Study limited access
dataset and incorporation in meta-analysis with eight
other studies.
Data sourceWHI CaD Study, a seven year, randomised,
placebo controlled trial of calcium and vitamin D (1g
calcium and 400 IU vitamin D daily) in 36282 community
dwelling postmenopausal women.
Main outcomemeasures Incidence of four cardiovascular
events and their combinations (myocardial infarction,
coronary revascularisation, death from coronary heart
disease, and stroke) assessedwith patient-level data and
trial-level data.
Results In the WHI CaD Study there was an interaction
between personal use of calcium supplements and
allocated calcium and vitamin D for cardiovascular
events. In the 16718 women (46%) who were not taking
personal calcium supplements at randomisation the
hazard ratios for cardiovascular events with calcium and
vitamin D ranged from 1.13 to 1.22 (P=0.05 for clinical
myocardial infarction or stroke, P=0.04 for clinical
myocardial infarction or revascularisation), whereas in
the women taking personal calcium supplements
cardiovascular risk did not alter with allocation to calcium
and vitamin D. In meta-analyses of three placebo
controlled trials, calcium and vitamin D increased the risk
of myocardial infarction (relative risk 1.21 (95%
confidence interval 1.01 to 1.44), P=0.04), stroke (1.20
(1.00 to 1.43), P=0.05), and the composite of myocardial
infarction or stroke (1.16 (1.02 to 1.32), P=0.02). In meta-
analyses of placebo controlled trials of calciumor calcium
and vitamin D, complete trial-level data were available for
28072 participants from eight trials of calcium
supplements and the WHI CaD participants not taking
personal calcium supplements. In total 1384 individuals
had an incident myocardial infarction or stroke. Calcium
or calcium and vitamin D increased the risk of myocardial
infarction (relative risk 1.24 (1.07 to 1.45), P=0.004) and
the composite of myocardial infarction or stroke (1.15
(1.03 to 1.27), P=0.009).
Conclusions Calcium supplements with or without
vitamin D modestly increase the risk of cardiovascular
events, especially myocardial infarction, a finding
obscured in the WHI CaD Study by the widespread use of
personal calcium supplements. A reassessment of the
role of calcium supplements in osteoporosis
management is warranted.
INTRODUCTION
Calcium supplements, with or without vitamin D, are
widely used for the prevention and treatment of osteo-
porosis. Recently, we reported increases in rates of
cardiovascular events in women allocated to calcium
supplements in the Auckland Calcium Study, a five
year randomised, placebo controlled trial in healthy
older women, in which cardiovascular events were
pre-specified secondary end points.1 Subsequently,
we carried out ameta-analysis of cardiovascular events
in randomised, placebo controlled trials of calcium
supplements (without vitamin D co-administration).2
Calcium supplements significantly increased the risk
of myocardial infarction by 31% in five trials involving
8151 participants where patient level data were avail-
able, and by 27% in 11 trials involving 11 921 partici-
pantswhere trial level datawere available.2 Therewere
no statistically significant increases in the risk of stroke;
the composite end point of myocardial infarction,
stroke, or sudden death; or death (relative risks or
hazard ratios ranged from 1.07 to 1.20), but the meta-
analyses did not have sufficient power to detect effect
sizes of these magnitudes.2
An important question that arises is whether co-
administered calcium and vitamin D affects cardio-
vascular risk. TheWomen’s Health Initiative reported
no adverse effect of calcium and vitamin D (1 g cal-
cium/400 IU vitamin D daily) on any cardiovascular
end point in their large (n=36 282), seven year, rando-
mised, placebo controlled trial.3 4 However, 54% of the
participants were taking personal (non-protocol)
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calcium supplements at randomisation and 47% were
taking personal vitamin D supplements, effectively
rendering this trial a comparison of higher dose and
lower dose calcium and vitamin D for most of the par-
ticipants.
Allowing clinical trial participants free access to the
intervention being studied is unusual and has the
potential to obscure both adverse and beneficial
effects. We hypothesised that the frequent personal
use of calcium supplements might have obscured an
adverse effect of calcium and vitamin D on cardio-
vascular risk. Therefore,we analysed the limited access
dataset of the Women’s Health Initiative Calcium/
Vitamin D Supplementation Study (WHI CaD
Study) to determine whether there were interactions
between personal use of calcium supplements and allo-
cation to calcium and vitamin D supplementation for
cardiovascular events. Using data from women not
using personal calcium supplements at randomisation
in the study, we have updated our previous meta-ana-
lysis to provide the best current estimate of the effects
of calcium supplements, with or without vitamin D, on
the risk of cardiovascular events.
METHODS
Analyses of WHI CaD Study
The design and results of the WHI CaD Study have
been published in full.3 4 Medical records related to
self reportedmedical events for myocardial infarction,
stroke, and coronary revascularisation were adjudi-
cated centrally by physician adjudicators using stan-
dardised definitions, and all deaths were also centrally
adjudicated.4 We obtained the WHI limited access,
clinical trials dataset from the National Heart Lung
and Blood Institute. A statistical analysis proposal
was submitted to the institute before the database was
made available.
We attempted to replicate the approach of theWHI
investigators where possible, carrying out pre-
specified analyses looking for interactions between
pre-specified subgroups based on use (no use v any
use) and dose (0, 1–499, 500–999, ≥1000 mg/day) of
personal calcium supplements at randomisation for
cardiovascular events. We pre-specified assessment
of four cardiovascular end points and their combina-
tions: myocardial infarction, coronary revascularisa-
tion (coronary artery bypass grafting or percutaneous
coronary intervention), death from coronary heart dis-
ease, and stroke. Serial electrocardiograms were car-
ried out in the WHI CaD Study, allowing detection
of silent myocardial infarctions. Because silent myo-
cardial infarctions were not determined in any of the
trials in ourmeta-analysis, we analysed data separately
for clinicalmyocardial infarctions and totalmyocardial
infarctions (including clinical and silent myocardial
infarction).We have reported four different composite
end points: total deaths from myocardial infarction or
coronary heart disease (themajor outcome reported in
theWHICaDStudy); clinicalmyocardial infarction or
coronary revascularisation (representing clinical cor-
onary heart disease events); clinical myocardial infarc-
tion or stroke (the composite end point most similar to
that used in ourmeta-analysis of calciummonotherapy
trials); and totalmyocardial infarction, coronary revas-
cularisation, and death from coronary heart disease
(representing all coronary heart disease events).
We have reported the baseline characteristics at the
time of randomisation to the WHI CaD Study,
whereas the WHI investigators reported these charac-
teristics at the time of entry to the WHI programme.
For bodymass index and for dietary and supplemental
calcium intake, we used the latest value recorded
between screening and onemonth after randomisation
to the study.
To assess the effect of calcium and vitamin D on the
time to first event for each end point, we used Cox
proportional hazards models stratified by age, preva-
lent cardiovascular disease at baseline, and randomisa-
tion status in the WHI Postmenopausal Hormone
TherapyTrials andDietaryModificationTrial, follow-
ing the approach of theWHI investigators.3 4 Compar-
isons between subgroups were assessed using
interaction terms. The assumption of proportional
hazards was tested by performing a test for
Table 1 | Characteristics of participants in the WHI CaD Study at randomisation, grouped by
personal use of calcium supplements. Values are percentages (numbers) unless stated
otherwise
Characteristic
No personal use of calcium Any personal use of calcium
CaD
(n=8429)
Placebo
(n=8289)
CaD
(n=9747)
Placebo
(n=9817)
Age (years):
Mean (SD) 62.9 (7.0) 62.9 (7.0) 63.9 (6.9) 63.9 (6.8)
50–60 39 (3259) 38 (3148) 31 (3030) 32 (3100)
60–70 43 (3633) 44 (3625) 49 (4741) 48 (4726)
≥70 18 (1537) 18 (1516) 20 (1976) 20 (1991)
Body mass index (kg/m2):
Mean (SD) 29.4 (5.9) 29.4 (6.0) 28.4 (5.7) 28.3 (5.7)
<30 59 (4974) 59 (4868) 66 (6421) 68 (6579)
Mean (SD) calcium intake (mg/day):
Personal supplement 0 0 582 (538) 582 (520)
Dietary intake 804 (489) 798 (475) 826 (454) 828 (451)
Mean (SD) blood pressure (mm Hg):
Systolic 126 (17) 126 (17) 125 (17) 125 (17)
Diastolic 75 (9) 75 (9) 74 (9) 74 (9)
Medical history*:
HRT use (in trials or personal) 49 (4120) 51 (4199) 54 (5301) 55 (5401)
High serum cholesterol requiring
pills
12 (898) 12 (870) 12 (1110) 12 (1094)
Cardiovascular disease 14 (1066) 15 (1074) 14 (1276) 15 (1333)
Hypertension 34 (2802) 35 (2861) 33 (3144) 32 (3100)
Stroke 1.0 (85) 1.2 (96) 0.7 (71) 1.0 (96)
Myocardial infarction 2.3 (191) 2.0 (167) 1.5 (149) 1.5 (147)
Smoking status*:
Never smoked 52 (4298) 53 (4307) 52 (5027) 53 (5121)
Former smoker 39 (3260) 38 (3154) 41 (3995) 41 (3979)
Current smoker 9 (772) 9 (732) 7 (633) 6 (624)
CaD=allocation to calcium and vitamin D supplement. HRT=hormone replacement therapy.
*Data recorded at randomisation except for medical history and smoking status, which were recorded at entry
to Women’s Health Initiative clinical trials programme: 91% of participants in the CaD Study entered at their
first annual visit for the WHI programme, and the remainder at their second annual visit.
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proportionality of the interaction between variables
included in the model and the logarithm of time.
Meta-analysis of calcium with or without vitamin D
Two recent systematic reviews have independently
reviewed the effects of calcium and vitamin D supple-
ments on vascular events.5 6 These reviews identified
two trials of co-administered calcium and vitamin D
with cardiovascular outcome data: the WHI CaD
Study and a small, one year trial of 191 participants
that reported 11 cardiovascular events during follow-
up but did not provide specific details about these
events.7 During the process of gathering data for our
meta-analysis of calcium monotherapy, we obtained
previously unpublished data from two studies that
compared co-administered calcium and vitamin D
with placebo.89 We therefore pooled data from these
two studies together with the results for the WHI CaD
Study participants who were not taking personal cal-
cium supplements at randomisation in a meta-analysis
of the effect of calcium and vitamin D on cardio-
vascular risk.
We then updated our previous meta-analysis of cal-
cium supplements by including the results for theWHI
CaD Study participants not taking personal calcium
supplements at randomisation, to determine the effect
of calcium with or without vitamin D on cardio-
vascular risk. Of note, only 1.2% of participants were
taking non-protocol calcium supplements in the trials
contributing patient-level data in our previous meta-
analysis of calcium supplements,2 and two of the six
studies contributing trial-level data permitted non-
protocol calcium supplements.9 10 We used the same
methods as for our previous meta-analysis:2 the effect
of calciumor calcium and vitaminDon the time to first
event was assessed with Cox proportional hazards
models stratified by study for patient-level data, and
trial-level summary data were pooled using random
effects models.2 The assumption of proportional
hazards was tested as described above.
All analyses were performed using SAS version 9.1
(SAS Institute, Cary NC, USA) or Comprehensive
Meta-analysis version 2 (Biostat, Englewood NJ,
USA). All tests were two tailed and P<0.05 was consid-
ered significant.
RESULTS
Reanalysis of the WHI CaD Study
Table 1 shows the characteristics of the participants at
randomisation to theWHICaDStudy groupedbyper-
sonal use of calcium supplements: 54% of participants
were taking personal calcium supplements. The base-
line characteristics of the participants allocated to cal-
cium and vitamin D or to placebo seemed well
matched for the subgroups defined by use of personal
calcium supplement. However, participants using per-
sonal calcium supplements differed from those not
using personal supplements in some factors associated
with cardiovascular disease: age, body mass index,
blood pressure, use of hormone replacement therapy,
history of myocardial infarction or stroke, and smok-
ing (P<0.05 for these variables) (table 1).
Table 2 shows the influence of personal use of cal-
cium supplements on the effect of calcium and vitamin
D on cardiovascular end points and mortality from all
causes. There were significant interactions between
allocation of calcium and vitamin D and personal use
of calcium supplements for clinical myocardial infarc-
tion, stroke, and the composite end point of myo-
cardial infarction or stroke. In women not taking
personal calcium supplements, the hazard ratios with
calcium and vitaminDwere 1.16 (P=0.04) for the com-
posite end point of clinical myocardial infarction or
coronary revascularisation, 1.16 (P=0.05) for clinical
myocardial infarction or stroke, 1.22 (P=0.05) formyo-
cardial infarction, and 1.13–1.20 for the other cardio-
vascular end points. By contrast, in women taking
personal calcium supplements, the hazard ratios for
these end points with calcium and vitamin D were
0.83–1.08.
Table 2 | Effect of allocation to calcium and vitamin D supplement on cardiovascular events among participants in the WHI CaD Study, grouped by personal
use of calcium supplements at randomisation. Values are numbers (incidence per 1000 patient years) of events unless stated otherwise
Cardiovascular end point
No personal use of calcium Any personal use of calcium
P value of
interaction*
CaD
(n=8429)
Placebo
(n=8289)
Comparison
CaD
(n=9747)
Placebo
(n=9817)
Comparison
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Clinical MI 209 (3.5) 168 (2.9) 1.22 (1.00 to 1.50) 0.05 180 (2.7) 196 (2.9) 0.92 (0.75 to 1.13) 0.4 0.04
Total MI† 222 (3.7) 182 (3.1) 1.20 (0.99 to 1.47) 0.07 193 (2.9) 207 (3.1) 0.94 (0.77 to 1.14) 0.5 0.07
Revascularisation 348 (5.9) 299 (5.1) 1.15 (0.98 to 1.34) 0.09 326 (4.9) 308 (4.6) 1.08 (0.93 to 1.27) 0.3 0.5
Stroke 196 (3.3) 163 (2.8) 1.17 (0.95 to 1.44) 0.1 156 (2.3) 189 (2.8) 0.83 (0.67 to 1.02) 0.08 0.02
Total MI or CHD death 268 (4.5) 229 (3.9) 1.15 (0.97 to 1.38) 0.1 238 (3.5) 247 (3.7) 0.97 (0.81 to 1.16) 0.7 0.1
Clinical MI or revascularisation 422 (7.2) 359 (6.2) 1.16 (1.01 to 1.34) 0.04 394 (5.9) 378 (5.6) 1.06 (0.92 to 1.23) 0.4 0.3
Clinical MI or stroke 386 (6.5) 326 (5.6) 1.16 (1.00 to 1.35) 0.05 324 (4.8) 370 (5.5) 0.88 (0.76 to 1.02) 0.09 0.006
Total MI, CHD death, or
revascularisation
476 (8.1) 417 (7.2) 1.13 (0.99 to 1.29) 0.07 447 (6.7) 421 (6.3) 1.08 (0.94 to 1.23) 0.3 0.5
Death from all causes 380 (6.3) 379 (6.4) 0.99 (0.86 to 1.14) 0.9 364 (5.4) 428 (6.3) 0.84 (0.73 to 0.97) 0.01 0.1
CaD=allocation to calcium and vitamin D supplement. MI=myocardial infarction. CHD=coronary heart disease.
*Interaction between CaD allocation and use or non-use of personal calcium supplements for each end point, testing the difference between subgroups.
†Includes clinically silent myocardial infarction diagnosed from changes in routine serial electrocardiograms.
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When the personal calcium supplement users were
divided into three groups by daily supplement intake
(1–499, 500–999, and ≥1000 mg/day), there was no
evidence of a relation between the dose of personal
calcium supplements and the risk of cardiovascular
events with randomisation to calcium and vitamin D
for these end points (fig 1). There were no significant
three-way interactions between calcium and vitaminD
allocation, personal calcium supplement use, and diet-
ary calcium intake (above or belowmedian) for cardio-
vascular end points (P>0.4). We repeated these
analyses in the subgroup of women not using personal
calcium supplements and found no interactions
between calcium and vitamin D allocation and dietary
calcium intake (above or below the median) for any
cardiovascular end point (P>0.5). Finally, we repeated
all these analyses using dietary calcium intake grouped
by tertile, and the results were similar. Together, these
analyses suggest that the relation between calcium and
vitaminD allocation and cardiovascular events is inde-
pendent of dietary calcium intake.
In a sensitivity analysis, we searched the WHI med-
ication database to identify participants potentially tak-
ing calcium supplements not captured elsewhere,
using WHI medication class codes for common cal-
cium supplement preparations (791000, 791099,
781230, 783500, 783600, 483000, 489900, and
489910).We identified 930 participants listed as taking
a calcium supplementbefore randomisation to calcium
and vitaminDbut recorded as having no supplemental
intake of calcium at randomisation.Whenwe repeated
the analyses including these women classified as using
personal calcium supplements, the results were similar
(data not shown).
Personal vitamin D supplements were used in com-
binationwith personal calcium supplements by 44% of
participants in the WHI database, and without perso-
nal calcium supplements by 3% of participants. When
we repeated the analyses grouping participants by per-
sonal use of calcium and/or vitamin D supplements,
the results were similar (data not shown).
Meta-analysis of calcium and vitamin D versus placebo
We analysed trials comparing co-administered cal-
cium and vitamin D with placebo. Complete trial-
level data for cardiovascular events were available for
20 090 participants from three trials—two trials with
previously unpublished data gathered during prepara-
tion of our previous meta-analysis of calcium
supplements,8 9 and data from the WHI CaD Study
participantswhowere not takingpersonal calcium sup-
plements at randomisation. In total, 465 individuals
had an incident myocardial infarction, 477 an incident
stroke, and 911 an incident myocardial infarction or
stroke during an average trial duration weighted by
study size of 6.2 years. Figure 2 shows that calcium
and vitamin D significantly increased the risk of myo-
cardial infarction (relative risk 1.21, P=0.04), stroke
(relative risk 1.20, P=0.05), and the composite of myo-
cardial infarction or stroke (relative risk 1.16, P=0.02).
In a sensitivity analysis, we also included data from a
study of calcium and vitamin D that only described
cardiovascular event data in detail on trial withdrawals
or deaths.7 The relative risks with calcium and vitamin
D were 1.22 (95% confidence interval 1.01 to 1.45,
P=0.03) for myocardial infarction, 1.20 (1.00 to 1.43,
P=0.05) for stroke, and 1.17 (1.03 to 1.32, P=0.02) for
the composite end point.
Clinical MI
  0
  1-499
  500-999
  ≥1000
Total MI†
  0
  1-499
  500-999
  ≥1000
Revascularisation
  0
  1-499
  500-999
  ≥1000
Stroke
  0
  1-499
  500-999
  ≥1000
Total MI/CHD death
  0
  1-499
  500-999
  ≥1000
Clinical MI/revascularisation
  0
  1-499
  500-999
  ≥1000
Clinical MI/stroke
  0
  1-499
  500-999
  ≥1000
Total MI/CHD death/revascularisation
  0
  1-499
  500-999
  ≥1000
0.50
CaD = allocation to calcium and vitamin D dietary supplement
MI = myocardial infarction
CHD = coronary heart disease
* Interaction between dose of personal calcium supplements and CaD allocation for each end point,
  testing the difference between subgroups
† includes clinically silent myocardial infarction diagnosed from changes in routine serial electrocardiograms
0.75 1.00 1.25 1.50 1.75 2.00
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(95% CI)
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86 (2.7)
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172 (5.4)
104 (4.8)
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196 (3.3)
77 (2.4)
56 (2.6)
23 (1.7)
268 (4.5)
125 (3.9)
71 (3.2)
42 (3.2)
422 (7.2)
205 (6.4)
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63 (4.8)
386 (6.5)
157 (4.9)
114 (5.2)
53 (4.0)
476 (8.1)
240 (7.5)
134 (6.2)
73 (5.6) 
CaD
168 (2.9)
99 (3.1)
65 (2.9)
32 (2.4)
182 (3.1)
105 (3.3)
68 (3.0)
34 (2.5)
299 (5.1)
157 (5.0)
95 (4.3)
56 (4.2)
163 (2.8)
97 (3.0)
57 (2.5)
35 (2.6)
229 (3.9)
126 (4.0)
79 (3.5)
42 (3.1)
359 (6.2)
189 (6.0)
121 (5.4)
68 (5.1)
326 (5.6)
188 (6.0)
116 (5.2)
66 (4.9)
417 (7.2)
212 (6.7)
133 (6.2)
76 (5.7) 
Placebo
0.2
0.3
0.7
0.05
0.5
0.7
0.02
0.8
P value for
interaction*
No (incidence/1000
patient years) of events
Fig 1 | Influence of personal calcium supplement dose at randomisation on the effect of calcium
and vitamin D on cardiovascular events in the WHI CaD Study
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All cause mortality was available from three studies
inwhich cardiovascular event datawere available: Bra-
zier et al,7 Grant et al for the RECORD trial,8 and the
WHI CaD Study. In these studies, 1200 deaths
occurred during follow-up, and the relative risk for
death (all causes) with calcium and vitamin D was
1.01 (0.90 to 1.12, P=0.9).
Meta-analysis of calcium with or without vitamin D versus
placebo
As the magnitude of the risk of cardiovascular events
with calcium and vitamin D was similar to that
observedwith calcium alone, we updated our previous
meta-analysis by incorporating the results for theWHI
CaD participants who were not taking personal cal-
cium supplements at randomisation, and the data
from the calcium and vitamin D arm of the Lappe
study;9 this arm was not included in our previous
meta-analysis.
Patient-level data
Patient-level data were available for 24 869 people in
six trials (WHICaDand five randomised, placebo con-
trolled trials of calcium supplements).1 8 11-15 In total,
631 individuals had an incident myocardial infarction,
669 an incident stroke, 1248 an incident myocardial
infarction or stroke, and 1765 died during a mean fol-
low-up of 5.9 years. Figure 3 shows that calcium or
calcium and vitamin D supplements increased the
risk of myocardial infarction (hazard ratio 1.26,
P=0.005), stroke (1.19, P=0.03), and the composite
end point of myocardial infarction or stroke (1.17,
P=0.005). The hazard ratio for death (all causes) was
1.04 (0.95 to 1.14, P=0.4).
The number needed to treat with calciumor calcium
andvitaminD for five years to cause one incident event
was 240 for myocardial infarction, 283 for stroke, and
178 for the composite end point. The corresponding
number needed to treat to prevent one fracture was
302. Treating 1000 people with calcium or calcium
and vitamin D for five years would cause an additional
sixmyocardial infarctions or strokes and prevent three
fractures.
Trial-level data
Complete trial-level datawere available for 28 072par-
ticipants in nine trials (the WHI CaD study and eight
randomised, placebo controlled trials of calcium
supplements).1 8 9 11-17 In total, 676 individuals had an
incident myocardial infarction, 764 an incident stroke,
1384 an incident myocardial infarction or stroke, and
1835 died during an average trial durationweighted by
study size of 5.7 years. Figure 4 shows that the results
were similar to the patient-level analyses. Calcium or
calcium and vitamin D supplements increased the risk
of myocardial infarction (relative risk 1.24, P=0.004)
and the composite of myocardial infarction/stroke
(1.15, P=0.009). The relative risk of death (all causes)
was 1.04 (0.95 to 1.13, P=0.5).
In a sensitivity analysis, we added all available data
from three further randomised, placebo controlled
trials of calcium supplements10 18 19 and one trial of cal-
cium and vitamin D supplements7 (limited to data on
deaths in trial or trial withdrawals) to the analysis of
complete trial-level data. Data were available for
29 277 participants (WHI CaD Study, 11 trials of cal-
cium supplements, and one trial of calcium and vita-
min D): 679 individuals had an incident myocardial
infarction, 768 an incident stroke, 1393 an incident
myocardial infarction or stroke, and 1857 died during
follow-up.With calciumor calciumandvitaminD sup-
plements, the relative risks were 1.25 (1.08 to 1.45,
P=0.003) for myocardial infarction, 1.15 (1.00 to 1.32,
P=0.06) for stroke, 1.15 (1.04 to 1.27, P=0.008) for the
composite of myocardial infarction or stroke, and 1.04
(0.95 to 1.13, P=0.4) for death.
DISCUSSION
In theWomen’s Health Initiative Calcium/Vitamin D
Supplementation (WHI CaD) Study personal use of
calcium supplement at randomisation significantly
influenced the effect of randomisation to calcium and
vitamin D on the risk of cardiovascular events. In the
entire WHI cohort, there were significant interactions
between calcium and vitamin D and personal calcium
supplement use for myocardial infarction and for
stroke. In the 46% of the WHI CaD participants who
were not taking personal calcium supplements at ran-
domisation, the hazard ratios for cardiovascular events
with calcium and vitamin D ranged from 1.13 to 1.22.
By contrast, in the participants taking personal calcium
supplements at randomisation, allocation to calcium
Myocardial infarction
  Grant 20058
  Lappe 20079
  WHI CaD 2007
Total
Test for heterogeneity: P=0.9, I2=0%
Stroke
  Grant 20058
  Lappe 20079
  WHI CaD 2007
Total
Test for heterogeneity: P=0.9, I2=0%
Myocardial infarction or stroke
  Grant 20058
  Lappe 20079
  WHI CaD 2007
Total
Test for heterogeneity: P=0.9, I2=0%
1.21 (1.01 to 1.44)
1.20 (1.00 to 1.43)
1.16 (1.02 to 1.32)
18
1
81
23
2
75
21
2
78
CaD = calcium and vitamin D
0.5 0.8 1.51 1.2 2 3
Study Relative risk
(95% CI)
Relative risk
(95% CI)
0.04
0.05
0.02
P
value
Weight
(%)
Favours
CaD
Favours
placebo
Fig 2 | Effect of calcium and vitamin D on cardiovascular events: based on trial-level data from
two randomised, placebo controlled trials of calcium and vitamin D89 and the WHI CaD Study
participants not taking personal calcium supplements at baseline. The first two trials included
calcium monotherapy and calcium and vitamin D groups: we included data only from the
calcium and vitamin D group compared with the placebo group
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and vitamin D did not alter cardiovascular risk. In
women not taking personal calcium supplements at
randomisation, the hazard ratios for clinical myo-
cardial infarction (1.22) and stroke (1.17) were similar
to those observed in our meta-analysis of trials of cal-
cium monotherapy (1.31 and 1.20, respectively).2
By itself, this analysis of the WHI CaD Study data
does not provide definitive evidence of an adverse
effect of calcium and vitamin D on cardiovascular
events. However, when these data are pooledwith pre-
viously unpublished data from two other placebo con-
trolled trials of calcium and vitamin D, there are
consistent increases in the risk ofmyocardial infarction
and stroke that are statistically significant and are of
similar size to the risks observed with calcium supple-
ments used without vitamin D. Further, when the
results for calcium and vitamin D are taken together
with those from trials of calcium used asmonotherapy,
they provide consistent evidence from 13 randomised,
placebo controlled trials involving about 29 000 parti-
cipants with about 1400 incident myocardial infarc-
tions and strokes that calcium supplements with or
without vitamin D increase the risk of cardiovascular
events.
The size of this increase is modest, about 25%–30%
formyocardial infarction and15%–20% for stroke, but,
because of the widespread use of calcium supplements
either alone or with vitamin D, even small increases in
cardiovascular disease incidence may translate to a
substantial population burden of disease, particularly
in older age groups. Furthermore, comparisons of the
benefits of calcium on fracture preventionwith the risk
of cardiovascular events suggest that the risk to benefit
profile is unfavourable: in our analysis, treating 1000
patients with calciumor calcium and vitaminD for five
years would cause an additional six myocardial infarc-
tions or strokes (number needed to harm of 178) and
prevent only three fractures (number needed to treat of
302).
Limitations of study
The current analysis has some limitations.We used the
publicly accessible, limited access dataset of the WHI
clinical trials for these analyses, so the analysis is lim-
ited to the information available in this dataset. Several
vascular end points are potentially evaluable; we pre-
specified those which allowed the most accurate com-
parisons with previous analyses. Subgroup analysis
raises several issues, including false positive results
and over-interpretation of findings.20 21 To minimise
these risks, we pre-specified the variable of interest
(personal calcium supplement use) for this analysis
before obtaining the WHI dataset, assessed its effect
using interaction tests, and followed recommended
approaches for subgroup analysis and inter
pretation.21 22 The hypothesis that the use of personal
calcium supplements might interact with the calcium
and vitamin D treatment effect in theWHI CaD Study
was based on plausibility from our finding in trials of
calcium monotherapy, and deviation from normal
clinical trial practice (allowing trial participants free
access to the intervention being studied) is unusual
and has the potential to mask both adverse and bene-
ficial effects.
We followed the approach of theWHI authors in not
adjusting P values for multiple subgroup analyses, and
instead estimated the likelihood of false positive tests,3
an approved approach for addressing multiplicity of
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(%
) Myocardial infarction
Hazard ratio 1.26, (95% CI 1.07 to 1.47), P=0.005
12 526
12 343
Calcium
Placebo
No at risk
11 822
11 725
9377
9262
6971
6855
2383
2332
583
599
0
1
2
3
4
5
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(%
) Stroke
Hazard ratio 1.19, (95% CI 1.02 to 1.39), P=0.03
12 526
12 343
Calcium
Placebo
No at risk
11 817
11 720
9391
9255
6982
6855
2383
2319
585
596
0
1
2
3
4
5
Years
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
(%
) Myocardial infarction or stroke
0 1 2
Hazard ratio 1.17, (95% CI 1.05 to 1.31), P=0.005
3 4 5 6 7 8 109
12 526
12 343
Calcium
Placebo
No at risk
11 746
11 660
9281
9167
6870
6761
2334
2287
572
586
0
2
4
6
8
10
Calcium
Placebo
Fig 3 | Effect of calcium supplements with or without vitamin D
on cardiovascular events: based on patient-level data. The
panels show the time to first event for 24869 participants in
five trials of calcium supplements,1811-15 and the WHI CaD
Study participants not taking personal calcium supplements
at baseline
RESEARCH
page 6 of 9 BMJ | ONLINE FIRST | bmj.com
statistical tests.23 Nine interaction tests were per-
formed: if the effect of calciumandvitaminDwas unre-
lated to personal calcium use and the end points were
independent, the probability of at least one false posi-
tive interaction test is <40%.22
Confounding is a possible explanation of our find-
ings as subgroup analysis may interfere with the balan-
cing effects of randomisation on potential
confounders. However, within each subgroup, the
baseline characteristics of the participants allocated to
calcium and vitamin D seemed well matched to those
allocated to placebo. In contrast, as expected, women
using personal calcium differed fromwomen not using
personal calcium in a number of factors that might
influence cardiovascular outcomes. However, the
WHI investigators have previously reported no signif-
icant interactions with these factors, calcium and vita-
minD, and risk of death frommyocardial infarction or
coronary heart disease—except for body mass index,
with obese women having a lower risk of death from
myocardial infarction or coronary heart disease with
calcium and vitamin D than non-obese women.4 Obe-
sity does not explain our findings since it was more
common in women not using personal calcium, and
would have tended to obscure an interaction effect.
In the WHI CaD participants the incidence of
cardiovascular events was relatively low, reflecting
the comparative youth of the cohort. Thus, despite its
size and long duration, theWHI CaD Study had insuf-
ficient power to detect small effect sizes, particularly
when subgroups are considered. For example, in
women not taking personal calcium supplements at
randomisation, the study had 80% power to detect a
33% increase in clinical myocardial infarction.
The WHI CaD Study accounts for 75%–80% of the
weighting in the meta-analyses of co-administered cal-
cium and vitamin D, and 45%–55% of the weighting in
the meta-analysis of calcium with or without vitamin
D. However, the results for the individual studies in
all the meta-analyses are quite consistent and do not
suggest an undue influence of a single outlying study
or WHI CaD.
Interpretation of results
For most of its participants, the WHI CaD Study
assessed the impact of adding calcium and vitamin D
to personal calcium supplements, effectively compar-
ing a higher dose of calcium with a lower dose of cal-
cium. By restricting the analyses to women not taking
personal calcium supplements, we were able to esti-
mate the effect of calcium and vitamin D on cardio-
vascular events, observing increased risks of these
events with calcium and vitamin D. In women taking
personal calcium supplements at randomisation, the
addition of calcium and vitamin D did not increase
cardiovascular risk, and the risk of cardiovascular
events with calcium and vitamin D was also not
affected by the dose of personal calcium supplements.
This suggests that there may not be a dose-response
relationship between calcium supplements and the
risk of cardiovascular events. Thus, even doses of
<500 mg/day might be associated with an increased
risk of cardiovascular events similar to doses
≥1000 mg/day. This would be consistent with the
notion that the abrupt change in plasma calcium con-
centration after supplement ingestion causes the
adverse effect, rather than it being related to the total
calcium load ingested.24 25
In the entire WHI cohort there was no significant
interaction between calcium and vitamin D, personal
calcium supplement use, andmortality—and therefore
no evidence of a difference in mortality risk with cal-
cium and vitamin D in the subgroups defined by
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personal calcium use. In women not taking personal
calcium supplements, no increase in mortality was
observed with calcium and vitamin D despite the
increased risk of cardiovascular events. The most
likely explanation is that participants in WHI were at
low risk of cardiovascular events and death. A 15%
increase in myocardial infarction and stroke would
lead to only a 1%–3% increase in total mortality if
10%–20% of the additional events led to death during
follow-up. The subgroup analysis did not have suffi-
cient power to detect such a difference, but the 95%
confidence intervals formortality (0.86 to 1.14) encom-
pass an effect of this size.
If calcium supplements do increase cardiovascular
risk it is important to consider the potential underlying
mechanisms.25 Calcium supplements acutely increase
serum calcium concentration by a modest amount,24
an effect that is sustained during long term treatment,
as evidenced by lower levels of parathyroid
hormone.15 Serum calcium concentrations are posi-
tively associated with carotid artery plaque
thickness,26 aortic calcification,27 incidence of myo-
cardial infarction,28-30 and mortality.31 These findings
are consistent with observational data suggesting
increased risk of cardiovascular events and death in
primary hyperparathyroidism, a condition in which
serum calcium concentration is elevated.32 33
The process of vascular calcification is a complex,
regulated process similar to osteogenesis.34 It is possi-
ble that the increase in serum calcium concentrations
from calcium supplements influences vascular calcifi-
cation by altering regulators of calcification such as
fetuin A, pyrophosphate, and bone morphogenic pro-
tein-7, or by directly binding to the calcium-sensing
receptor that is expressed on vascular smooth muscle
cells.25 Exposing cultures of vascular smooth muscle
cells to increased concentrations of calcium results in
increased mineralisation of the cultures.35 Supporting
this hypothesis are studies of patients with renal
impairment, in whom calcium supplements accelerate
vascular calcification and increase mortality in both
dialysis and pre-dialysis populations.36-38
It is also possible that calcium supplements
adversely affect risk of arterial thrombus formation.
Acute hypercalcaemia in rats increases blood
coaguability,39 potentially via an effect on platelets
since calcium-sensing receptors are found on these
cells.40
Therefore, extracellular calcium concentrations
might affect the function of several cells that are impli-
cated in the pathogenesis of vascular events. All these
possibilities require further evaluation.
Conclusions
Calcium and vitaminD supplements increased the risk
of cardiovascular events in the WHI CaD participants
who were not taking personal calcium supplements at
the time of randomisation. When these results are
taken together with the results of other clinical trials
of calcium supplements, with or without vitamin D,
they strongly suggest that calcium supplements mod-
estly increase the risk of cardiovascular events, particu-
larly myocardial infarction. These data justify a
reassessment of the use of calcium supplements in
older people.
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